Grifols

Grifols

Grifols

Spanish pharmaceutical and chemical manufacturer

Grifols, S.A. (Catalan: [ˈɡɾifuls]) is a Spanish multinational pharmaceutical and chemical manufacturer. Principally a producer of blood plasma–based products, a field in which it is the European leader and largest worldwide,[3][4] the company also supplies devices, instruments, and reagents for clinical testing laboratories.

Quick Facts Company type, Traded as ...

History

Human immunoglobulin for anti-tetanus use and antithrombin produced by Grifols.

Grifols' origin lies in the laboratory founded in 1940 in Barcelona by Dr Josep A. Grífols Roig, a hematologist and scientist (although its origin dates back to the Instituto Central de Análisis Clínicos, a company founded in 1909 by Josep Antonio Grífols Roig, which will be a pioneer in Spain in clinical analysis and in the introduction of blood conservation and transfusion techniques).[5] His son, Dr Josep A. Grifols Lucas was the first researcher to publish the plasmapheresis procedure in 1952.[6] The company introduced its liquid IVIG product into the European market in the mid-1990s.

Probitas Pharma, S.A. was incorporated with high limited liability under Spanish law on 22 June 1987; on 27 June 2005 the company changed its name to Grifols, S.A.[7][self-published source] In 2003 the company acquired certain assets of the Los Angeles–based Alpha Therapeutic (US subsidiary of Mitsubishi Pharma) as the basis of its American expansion.[8] On May 17, 2006, Grifols securities were listed on Spain's Mercado Continuo.[9]

In 2009, CSL Limited attempted to takeover Talecris Biotherapeutics (the former plasma business of Bayer HealthCare LLC, Biological Products Division)[10] for $3,1 billion but was stopped by the Federal Trade Commission.[11] On 1 June 2011, a year after announcing the $4 billion deal, Grifols completed a takeover of Talecris Biotherapeutics, headquartered in Research Triangle Park in North Carolina, with over 2000 employees.[12]

Grifols acquired the blood transfusion diagnostics unit from Novartis in 2013 as a "platform for global expansion".[4] This unit is based in Emeryville, California and was a part of Chiron acquired by Novartis in 2006.[4]

In 2015, the company acquired a 45% stake in Alkahest as part of planned co-development of "plasma-based products for the treatment of cognitive decline in aging and disorders of the CNS, including Alzheimer's."[13] In 2020 Grifols acquired the remaining stock of Alkahest “bringing its ownership of Alkahest to 100%”.[14]

In December 2016, Grifols acquired Hologics interest in their existing joint blood screening unit for $1.85 billion[15]

In February 2022, Biotest AG and four other companies were fined by the Romanian Competition Council for having limited or interrupted the supply of essential immunoglobins with the goal of pressuring the government into removing a tax on their blood products from 2015 to 2018.[16] Biotest was acquired by Grifols in April 2022.[17]

Main products

Grifols is the major world supplier of IVIG, albumin, Factor VIII and other plasma-derived products.[citation needed]

Operations

In 2007 the company had 3.6 million litres per year of blood fractionation capacity from three plants, one at Parets del Vallès near Barcelona in Spain (2.1 million litres per year), another in Los Angeles (1.5 million litres but being expanded to 2.2 million litres), and a site in Clayton, North Carolina. In the United States the company owns 230 plasmapheresis centres, where it collects around 5.8 million litres of plasma per year.[citation needed]

Ownership

Grifols was listed on the Madrid Stock Exchange in May 2006.[18] The stock became part of the IBEX 35 index in January 2008.

References

  1. [1]
    "2022 Annual Report (Form 20-F)". US Securities and Exchange Commission. Retrieved 2023-04-18.
  2. [2]
    "Grifols appoints new CEO Nacho Abia to the board". Nasdaq. Retrieved 2024-04-03.
  3. [3]
    Smyth, Sharon; Gore, Gareth (23 June 2008). "Santander, Sabadell, Sol Melia, Urbas: Iberia Preview". Bloomberg. Archived from the original on 23 October 2012. Retrieved 2009-01-18.
  4. [4]
    "Novartis Sells Blood Transfusion Dx Unit to Grifols". Genetic Engineering & Biotechnology News (Paper). Vol. 33, no. 21. December 2013. p. 10.
  5. [5]
    Grupo Enciclopedia Catalana. "Grifols". Retrieved 20 July 2020.
  6. [6]
    Grífols-Lucas, JA (1952). "Use of plasmapheresis in blood donors". British Medical Journal. 1 (4763): 854. doi:10.1136/bmj.1.4763.854. PMC 2023259. PMID 14916171.
  7. [7]
    "Grifols S.A. (formerly Probitas Pharma S.A.) And Subsidiaries: Consolidated Annual Accounts prepared in accordance with International Financial Reporting Standards as adopted for use in the European Union and Consolidated Directors' Report". 31 December 2005. Retrieved 2016-02-03.
  8. [8]
    "Mitsubishi Pharma to Withdraw from US Plasma Fractionation Business as US Subsidiary Transfers Operations" (Press release). Mitsubishi Pharma Corporation. 10 April 2003. Retrieved 2016-02-03.
  9. [9]
    "News in brief: Third time lucky for Grifols". Financial News. London. 1 May 2006. Retrieved 2016-02-03.
  10. [10]
    "Announcing the Launch of Talecris Biotherapeutics" (Press release). Talecris. 1 April 2005. Retrieved 2016-02-03 – via BusinessWire.
  11. [11]
    "FTC Authorizes Suit To Stop CSLs Proposed $3.1 Billion Acquisition of Talecris Biotherapeutics". 2009-05-27. Retrieved 2016-02-03.
  12. [12]
    Wolf, Alan M. (2011-06-02). "Spanish buyer set to take over Talecris". News & Observer. Archived from the original on 2011-06-05. Retrieved 2011-06-02.
  13. [13]
    "Grifols Makes $37.5M Investment in Alkahest". News: Industry Watch. Genetic Engineering & Biotechnology News (Paper). 35 (7): 10. 1 April 2015.
  14. [14]
    "Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome". 7 September 2020. Retrieved 2021-09-11.
  15. [15]
    Grifols Buys Hologic’s Share in Blood Screening Unit for $1.85B. Retrieved 15 December 2016.
  16. [16]
    "Romanian competition body fines five European pharma companies on collusion".
  17. [17]
    "Grifols completes the acquisition of Biotest: a strategic and transformational transaction to accelerate growth and innovation".
  18. [18]
    Dowsett, Sonya (19 January 2007). "Blood firm Grifols sees 2006 sales up 22 pct". Reuters. Retrieved 2009-01-18.
Wikimedia Commons has media related to Grifols.
Share this article:

This article uses material from the Wikipedia article Grifols, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.